Search results | Galderma

You searched for: «【✈️ Telegram ID: KPU77】 대성피 성인 피시방 안전 보장 100% 알거래 중개소 리스트 - 용인»

Galderma marks Rosacea Awareness Month with new insights into why some patients are self-treating and launches social media campaign to reinforce hidden impact of the disease

Galderma extends its commitment to understanding the beyond the visible impact of rosacea with new patient insights supporting healthcare professionals’ understanding of patient behavior and revealing possible motivations for not reconsulting

Landmark global Galderma survey shows 9 out of 10 people are affected by skin quality concerns

World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin¹

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Upfront and approval payments of up to $15 million
Tiered royalties ranging from mid- to high-teen percentage of net sales
Sol-Gel option to regain commercialization rights 5 years following first commercialization

Galderma Announces Results of ALAMO: A Real-World, Phase 4 Study Demonstrating Efficacy and Safety of Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Plus Oral Doxycycline 200 mg in Treating Severe Inflammatory Acne

Study Results Published in Journal of Drugs in Dermatology

TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously

Phase III READY-3 study met its co-primary endpoints, with RelabotulinumtoxinA significantly improving both frown lines and crow’s feet when treated alone or simultaneously¹
Results demonstrate high patient satisfaction at one month and long duration of effect for six months¹
Data further reinforce Relab